natur
occur
strain
newcastl
diseas
viru
ndv
current
investig
multipl
clinic
trial
oncolyt
cancer
therapi
unit
state
abroad
previous
report
first
time
develop
recombin
ndv
design
enhanc
cancer
therapeut
efficaci
specif
shown
ndv
engin
express
gener
robust
therapeut
respons
associ
increas
tumorspecif
tcell
infiltr
intratumor
administr
mice
demonstr
therapeut
respons
depend
cell
investig
potenti
focu
ndvinduc
immun
respons
toward
tumorassoci
antigen
taa
enhanc
inher
therapeut
efficaci
ndv
found
intratumor
treatment
tumorbear
mice
recombin
ndv
express
model
taa
elicit
enhanc
tumorspecif
respons
result
signific
increas
number
complet
tumor
regress
compar
control
ndv
addit
coadministr
ndv
express
model
taa
ndv
express
enhanc
taadirect
respons
led
complet
tumor
regress
result
show
taadirect
immunotherapi
oncolyt
recombin
ndv
alon
combin
result
enhanc
therapeut
efficaci
warrant
consider
develop
cancer
therapi
base
use
oncolyt
ndv
result
genet
alter
tumor
express
uniqu
antigen
recogn
cell
tumorassoci
antigen
taa
tumorspecif
antigen
share
antigen
specif
particular
cell
lineag
differenti
antigen
mutat
protein
antigen
deriv
oncogen
viral
antigen
antigen
process
present
major
histocompat
complex
class
major
histocompat
complex
class
ii
molecul
prime
activ
cell
numer
studi
indic
immun
system
potenti
elicit
cellmedi
tumorspecif
immun
respons
capabl
larg
tumor
destruct
despit
fact
cancer
cell
even
express
antigen
may
elicit
robust
immun
respons
case
cancer
cell
escap
immun
detect
origin
normal
cell
activ
antigenpres
cell
nonactiv
antigenpres
cell
present
uniqu
cancer
antigen
without
costimul
could
lead
toler
specif
cell
encount
taa
absenc
costimul
may
becom
ignor
anerg
apoptot
therefor
although
robust
taaspecif
immun
respons
capabl
tumor
erad
toler
gener
oncogen
develop
may
lead
larg
tumor
growth
although
taa
toler
present
signific
challeng
cancer
immunotherapi
barrier
overcom
interestingli
sever
virus
strong
induc
immun
respons
offer
attract
strategi
cancer
therapi
stimul
patient
immun
system
within
tumor
order
overcom
immunolog
barrier
abil
oncolyt
virus
induc
tumorspecif
immun
respons
well
document
test
clinic
trial
also
recent
report
group
intratumor
inject
recombin
newcastl
diseas
viru
ndv
caus
complet
tumor
regress
tumorbear
mice
protect
mice
subsequ
tumor
challeng
parent
tumor
cell
previou
report
found
intratumor
inject
result
complet
regress
mice
bear
subcutan
implant
autolog
colon
carcinoma
cell
addit
recombin
express
enhanc
therapeut
efficaci
treatment
result
mice
undergo
complet
regress
consist
previou
report
use
hsvexpress
ref
mice
underw
complet
regress
either
treatment
protect
subsequ
tumor
rechalleng
highlight
induct
potent
longlast
antitumor
adapt
immun
respons
mice
treat
also
increas
tcell
infiltr
enhanc
tumorspecif
adapt
immun
respons
correl
enhanc
therapeut
respons
investig
whether
express
taa
genet
engin
ndv
could
focu
ndvinduc
adapt
tcell
respons
toward
taa
enhanc
ndv
therapeut
efficaci
qualiti
immun
respons
antigen
depend
mani
interrel
factor
includ
tissu
distribut
preexist
toler
tcell
repertoir
immun
activ
studi
abil
ndv
induc
taaspecif
respons
use
tumor
model
system
express
murin
tumor
cell
model
express
major
histocompat
complex
class
l
epitop
amino
acid
sequenc
tphparigl
ndv
allow
evalu
singl
tcell
antigen
determin
enhanc
regress
establish
tumor
ndv
tcell
epitop
previous
report
effect
taa
target
gener
cell
colon
carcinoma
cell
express
xenogen
antigen
model
exampl
tumor
express
uniqu
nonself
antigen
viral
antigen
mutat
selfantigen
frameshift
mutat
complementari
dna
encod
tcell
epitop
tphparigl
minig
clone
ndv
pv
gene
fulllength
infecti
clone
ndv
ndv
figur
chose
backbon
contain
multibas
cleavag
site
f
protein
viru
base
previou
studi
show
increas
antitumor
efficaci
viru
compar
wildtyp
parent
ndv
strain
proper
express
ndv
replicationtranscript
machineri
minig
epitop
flank
ndvspecif
transcript
start
stop
signal
addit
epitop
express
endoplasm
reticuluminsert
sequenc
known
enhanc
immunogen
encod
epitop
direct
epitop
endoplasm
reticulum
like
enhanc
antigen
present
endoplasm
reticulumtarget
tcell
epitop
least
immunogen
fulllength
protein
deriv
recombin
rescu
previous
describ
plaqu
purifi
growth
kinet
viru
cell
compar
previous
report
recombin
figur
previous
report
oncolyt
therapi
recombin
express
associ
increas
number
tcell
tumor
infiltr
adapt
antitumor
immun
respons
base
previou
result
recent
public
known
tcell
growth
factor
investig
whether
oncolyt
therapi
depend
cell
purpos
test
therapeut
efficaci
recombin
nude
mous
model
nude
mice
sever
defici
cell
produc
small
number
cell
due
genet
mutat
gene
caus
development
deterior
thymu
nude
mice
maintain
normal
number
macrophag
natur
killer
nk
cell
antigenpres
cell
function
normal
complement
activ
balbc
nude
mice
subcutan
inject
syngen
colon
carcinoma
cell
inject
cell
allow
establish
solid
tumor
tumor
reach
mm
diamet
day
mice
treat
plaqueform
unit
pfu
recombin
ndv
everi
day
total
four
intratumor
inject
seen
figur
nude
mice
treat
undergo
singl
complet
regress
tumor
growth
impair
compar
phosphatebuff
salinetr
nude
mice
result
obtain
nude
mice
treat
ndv
viru
case
use
control
viru
use
cell
express
contrast
previous
report
result
immunocompet
balbc
mice
underw
complet
regress
follow
intratumor
treatment
mice
follow
treatment
result
highlight
depend
tcell
function
treatment
group
illustr
cell
critic
therapeut
efficaci
know
oncolyt
properti
vivo
tcell
depend
next
investig
whether
express
model
taa
could
enhanc
antitumor
efficaci
intratumor
inject
immunocompet
wildtyp
balbc
mice
balbc
mice
subcutan
implant
syngen
cancer
cell
cell
repres
tumor
cell
line
deriv
cell
express
longtermin
repeat
moloney
murin
leukemia
viru
complementari
dna
day
tumor
mm
diamet
mice
intratumor
treat
pfu
phosphatebuff
salin
everi
day
total
four
inject
seen
figur
intratumor
inject
result
higher
percentag
complet
regress
mice
harbor
tumor
compar
treatment
control
viru
p
enhanc
respons
absent
tumorbear
mice
treat
importantli
mice
complet
tumor
regress
protect
rechalleng
contralater
flank
day
posttumor
treatment
initi
tumor
cell
origin
bore
data
shown
wt
tumorbear
mice
underw
complet
tumor
regress
capabl
induc
protect
immun
cell
suggest
inher
tumorspecif
antigen
present
cell
line
capabl
mediat
adapt
immun
recognit
challeng
protect
result
highlight
induct
potent
adapt
immun
respons
capabl
reject
tumor
challeng
assess
induct
tumorspecif
cellular
immun
respons
three
mice
per
group
treat
figur
newcastl
diseas
viru
ndv
treat
tumorbear
mice
anim
bear
tumor
treat
figur
tumordrain
lymph
node
pool
three
mice
per
group
day
posttreat
initi
lymph
node
ln
cell
dissoci
cocultur
irradi
cell
plate
alon
assay
product
day
later
mean
sd
n
ln
cell
media
alon
produc
detect
data
shown
b
ln
cell
cultur
minig
peptid
control
peptid
assay
product
day
later
product
control
peptid
undetect
data
shown
gfp
green
fluoresc
protein
pb
phosphatebuff
salin
tumordrain
lymph
node
ln
cell
harvest
cocultur
irradi
cell
supernat
cocultur
assay
releas
measur
enzymelink
immunosorb
assay
result
show
day
cocultur
cell
ln
cell
mice
produc
significantli
higher
level
ln
cell
phosphatebuff
salin
mice
figur
howev
ln
cell
mice
treat
ndv
produc
cocultur
cell
ln
cell
mice
treat
respons
correl
increas
percentag
complet
tumor
regress
follow
ndv
treatment
compar
treatment
figur
separ
experi
ln
cell
cultur
taa
peptid
minig
tphparigl
irrelev
control
peptid
amqmlketi
product
measur
supernat
day
incub
seen
figur
ln
cell
mice
minigalspecif
induct
product
respons
undetect
cultur
control
peptid
data
shown
ln
cell
tumorbear
mice
treat
also
produc
minigalspecif
immun
respons
potent
mice
coadministr
ndv
tumorbear
mice
result
tumor
regress
next
want
determin
whether
coadministr
ndv
synergist
therapeut
effect
tumor
express
ten
mice
per
group
implant
tumor
cell
treat
alon
combin
ndv
control
viru
use
shown
figur
treatment
tumorbear
mice
ndv
result
statist
signific
number
tumor
regress
treatment
control
p
moreov
cotreat
result
mice
undergo
complet
regress
compar
mice
treat
alon
control
cotreat
group
p
mice
complet
tumor
regress
protect
rechalleng
contralater
flank
day
posttumor
treatment
initi
cell
figur
day
five
mice
challeng
syngen
renal
cell
carcinoma
cell
line
renca
control
specif
cell
mice
naiv
control
mice
develop
visibl
tumor
day
renca
cell
implant
data
shown
assess
induct
tumorspecif
immun
respons
coadministr
ln
cell
treat
mice
harvest
cocultur
either
cell
supernat
measur
releas
result
show
day
cocultur
tumor
cell
ln
cell
mice
treat
togeth
produc
significantli
treatment
one
virus
plu
control
alon
synergist
effect
specif
minig
antigen
seen
cell
use
stimul
cell
figur
also
observ
ln
cell
stimul
minig
peptid
figur
negat
contribut
nk
cell
repeat
assay
ln
cell
deplet
nk
cell
magnet
cell
sort
separ
observ
similar
result
figur
addit
fluorescenceactiv
cellsort
analysi
observ
intern
cytokin
stain
cell
hour
cocultur
cell
figur
find
suggest
tcell
investig
use
revers
genet
enhanc
therapeut
antitumor
efficaci
ndv
elicit
taafocus
immun
respons
first
demonstr
depend
cell
ndv
oncolyt
therapi
murin
colon
carcinoma
tumor
model
previous
report
induct
adapt
immun
respons
tumor
cell
result
tumorbear
mice
undergo
complet
tumor
regress
follow
intratumor
inject
importantli
induc
antitumor
adapt
respons
surviv
treat
mice
capabl
protect
subsequ
tumor
rechalleng
contrast
result
figur
nude
mice
subcutan
implant
cell
undergo
tumor
regress
upon
ndv
oncolyt
therapi
mice
addit
found
tumorbear
nude
mice
treat
express
tcell
growth
factor
also
unrespons
treatment
therapi
although
exclud
role
cell
experi
might
support
cellular
function
differ
direct
lysi
tumor
cell
conclud
presenc
cell
necessari
antitumor
efficaci
ndv
highlight
import
cell
ndv
oncolyt
therapi
contrast
viru
oncolyt
agent
vesicular
stomat
viru
mediat
destruct
tumor
mice
absenc
cell
probabl
due
robust
cytolyt
activ
higher
level
replic
vesicular
stomat
viru
tumor
cell
compar
ndv
next
investig
potenti
enhanc
cellmedi
oncolyt
efficaci
ndv
express
taa
ndv
would
result
overexpress
taa
ndvinfect
cell
approach
result
enhanc
therapeut
efficaci
ndv
tumor
express
taa
specif
intratumor
inocul
oncolyt
ndv
express
model
taa
minig
induc
enhanc
taaspecif
immun
respons
result
increas
percentag
regress
tumor
express
taa
mice
compar
mice
controltr
mice
furthermor
tumorbear
mice
express
model
taa
tumorbear
mice
respond
similar
treatment
ndv
demonstr
specif
respons
taa
also
found
coexpress
tcell
growth
factor
taa
ndv
significantli
improv
celldirect
therapeut
respons
result
mice
undergo
complet
tumor
regress
p
mice
signific
increas
tumorspecif
tcell
immun
respons
increas
cellspecif
respons
taa
peptid
enhanc
therapeut
respons
might
result
increas
tcell
infiltr
within
tumor
mice
treat
ndv
result
increas
antitumorspecif
adapt
respons
report
previous
revers
anergi
cell
upon
signal
nonetheless
increas
taaspecif
adapt
respons
upon
treatment
translat
increas
therapeut
respons
ndv
consist
previou
report
observ
use
poxviru
taadirect
therapi
interestingli
high
level
incub
cell
produc
ln
cell
deriv
tumorbear
mice
treat
specul
high
level
product
explain
broaden
effect
other
observ
immun
specif
antigen
exampl
markiewicz
et
al
shown
cure
mice
vaccin
tumor
peptid
reject
tumorderiv
cell
line
express
vaccin
peptid
also
mice
vaccin
dna
encod
reject
neu
neg
tumor
mice
phenomenon
refer
antigen
cascad
also
observ
sever
preclin
clinic
report
ndv
possess
numer
characterist
make
ideal
vaccin
vector
recogn
effect
vaccin
vector
capabl
elicit
potent
immun
respons
target
encod
vaccin
antigen
abil
recombin
ndv
vector
use
prophylact
vaccin
vector
har
sever
group
use
vaccin
respiratori
syncyti
viru
highli
pathogen
avian
influenza
viru
simian
immunodefici
viru
human
parainfluenza
viru
type
infecti
bursal
diseas
viru
well
sever
acut
respiratori
syndromeassoci
coronaviru
studi
found
ndv
vector
express
foreign
antigen
capabl
induc
protect
immun
sever
pathogen
multipl
anim
model
includ
murin
avian
nonhuman
primat
importantli
ndv
vaccin
vector
induc
humor
cellular
immun
express
recombin
antigen
recombin
virusbas
immunotherapi
recogn
one
potent
induc
taadirect
ctl
tumorspecif
ctlmediat
respons
tradit
sought
therapeut
cancer
develop
well
cancer
vaccin
import
mediat
antitumor
respons
vivo
oncolyt
ndv
demonstr
therapeut
efficaci
sever
clinic
trial
administr
ex
vivo
ndvinfect
oncolys
cancer
patient
result
increas
tumorspecif
tcell
respons
associ
prolong
surviv
gener
antigenspecif
immun
respons
may
easili
translat
prophylact
therapi
prevent
number
cancer
necess
therapeut
agent
given
subsequ
cancer
diagnosi
tradit
focu
cancer
therapi
demonstr
abil
direct
target
taa
immun
respons
recombin
ndv
encod
model
taa
virusbas
cancer
vaccin
target
specif
taa
clinic
cancer
therapi
enter
clinic
trial
report
statist
signific
therapeut
respons
howev
presenc
preexist
neutral
antibodi
viral
vector
major
concern
futur
develop
concern
less
import
ndvtaa
vaccin
therapi
due
low
preval
prior
exposur
human
avian
paramyxoviru
ndv
antigen
distinct
common
human
pathogen
vaccin
make
immunogen
gener
human
popul
without
concern
preexist
neutral
antibodi
howev
ndv
caus
hemagglutin
bind
sialic
acid
therebi
possibl
limit
effect
intraven
deliveri
reason
investig
intratumor
inject
oncolyt
ndv
deliveri
rout
nonetheless
intraven
deliveri
ndv
demonstr
therapeut
efficaci
preclin
clinic
studi
may
possibl
rout
deliveri
form
cancer
previous
report
first
time
use
revers
genet
enhanc
cancer
therapeut
efficaci
oncolyt
ndv
investig
potenti
enhanc
therapeut
efficaci
recombin
ndv
taadirect
therapi
ndv
encod
model
tcell
taa
epitop
elicit
target
taadirect
adapt
immun
respons
result
statist
signific
increas
therapeut
efficaci
addit
respons
could
enhanc
cotreat
ndv
express
result
mice
undergo
complet
tumor
regress
tumor
model
system
result
present
first
demonstr
abil
recombin
ndv
express
taa
use
therapeut
cancer
vaccin
vector
cell
cultur
cell
line
gener
provid
nichola
p
restifo
nation
cancer
institut
nation
institut
health
bethesda
md
maintain
rosewel
park
memori
medium
supplement
heatinactiv
fetal
bovin
serum
sigmaaldrich
streptomycin
penicillin
lglutamin
madindarbi
bovin
kidney
cell
maintain
dulbecco
modifi
eagl
medium
rich
organ
medium
respect
chicken
embryo
fibroblast
cell
prepar
previous
describ
maintain
minimum
essenti
medium
dulbecco
modifi
eagl
medium
minimum
essenti
medium
rich
organ
medium
supplement
fetal
bovin
serum
streptomycin
penicillin
ndv
complementari
dna
sequenc
deriv
hitchner
lentogen
strain
commonli
use
live
attenu
vaccin
chicken
recent
use
phase
iii
oncolyt
clinic
trial
recombin
ndv
virus
gener
previous
describ
sequenc
revers
transcript
pcr
fidel
virus
plaqu
purifi
grown
old
pathogenfre
chicken
egg
charl
river
laboratori
spafa
viru
stock
prepar
test
contamin
streak
sheep
blood
agar
plate
incub
overnight
data
shown
engin
express
model
taa
gfp
gene
cassett
insert
diagram
figur
viru
prepar
titrat
plaqu
purif
madindarbi
bovin
kidney
cell
growth
curv
assess
immunofluoresc
cell
use
polyclon
antibodi
ndv
anim
studi
procedur
involv
anim
follow
nation
institut
health
guidelin
approv
perform
accord
specif
guidelin
institut
anim
care
use
committe
mount
sinai
school
medicin
sixweekold
femal
balbc
mice
purchas
tacon
farm
hous
pathogenfre
environ
balbc
wild
type
balbc
nude
mice
subcutan
implant
either
cell
tumor
reach
size
mm
diamet
day
mice
intratumor
treat
phosphatebuff
salin
pfu
indic
viru
tumor
volum
monitor
everi
day
use
digit
calip
two
dimens
tumor
volum
calcul
use
follow
formula
tumor
volum
v
smallest
measur
diamet
l
larger
diamet
mice
intratumor
inject
pfu
recombin
ndv
everi
day
four
inject
total
mice
cotreat
group
receiv
pfu
supplement
pfu
cotreat
viru
total
volum
anim
kill
tumor
size
reach
mm
dimens
defin
experiment
time
point
tumordrain
ln
dissect
three
mice
per
group
day
posttreat
initi
manual
dissoci
singlecel
suspens
approxim
ln
cell
seed
well
triplic
cocultur
irradi
wt
cell
ratio
supernat
collect
day
incub
releas
assay
enzymelink
immunosorb
assay
kit
r
system
follow
supplier
protocol
peptidespecif
respons
measur
incub
ln
cell
per
group
either
minigalspecif
peptid
tphparigl
control
peptid
amqmlketi
human
immunodefici
viru
supernat
collect
day
incub
assay
enzymelink
immunosorb
assay
kit
r
system
follow
supplier
protocol
indic
ln
cell
two
mice
per
treatment
group
deplet
nk
cell
microbead
separ
use
antink
ab
accord
manufactur
protocol
miltenyi
biotec
assay
upon
cocultur
irradi
cell
day
purifi
ln
cell
two
mice
per
treatment
group
cocultur
irradi
cell
hour
presenc
golgistop
bd
pharmingen
end
incub
cell
collect
stain
respect
bd
pharmingen
permeabil
cytofix
cytoperm
bd
pharmingen
follow
stain
ebiosci
data
analyz
flow
cytometri
cytom
machin
beckman
coulter
